Search Results - "Habjan, Eva"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor by Habjan, Eva, Ho, Vien Q T, Gallant, James, van Stempvoort, Gunny, Jim, Kin Ki, Kuijl, Coen, Geerke, Daan P, Bitter, Wilbert, Speer, Alexander

    Published in Disease models & mechanisms (01-12-2021)
    “…Finding new anti-tuberculosis compounds with convincing in vivo activity is an ongoing global challenge to fight the emergence of multidrug-resistant…”
    Get full text
    Journal Article
  2. 2

    Dysregulation of Mycobacterium marinum ESX-5 Secretion by Novel 1,2,4-oxadiazoles by Ho, Vien Q T, Rong, Mark K, Habjan, Eva, Bommer, Samantha D, Pham, Thang V, Piersma, Sander R, Bitter, Wilbert, Ruijter, Eelco, Speer, Alexander

    Published in Biomolecules (Basel, Switzerland) (21-01-2023)
    “…The ESX-5 secretion system is essential for the viability and virulence of slow-growing pathogenic mycobacterial species. In this study, we identified a…”
    Get full text
    Journal Article
  3. 3

    Diving into drug-screening: zebrafish embryos as an in vivo platform for antimicrobial drug discovery and assessment by Habjan, Eva, Schouten, Gina K, Speer, Alexander, van Ulsen, Peter, Bitter, Wilbert

    Published in FEMS microbiology reviews (08-05-2024)
    “…The rise of multidrug-resistant bacteria underlines the need for innovative treatments, yet the introduction of new drugs has stagnated despite numerous…”
    Get full text
    Journal Article
  4. 4

    Heterologous Expression of ethA and katG in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis by Ho, Vien Q T, Verboom, Theo, Rong, Mark K, Habjan, Eva, Bitter, Wilbert, Speer, Alexander

    Published in Antimicrobial agents and chemotherapy (18-03-2021)
    “…Screening strategies for antituberculosis compounds using are time consuming and require biosafety level 3 (BSL3) facilities, which makes the development of…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Modulating mycobacterial envelope integrity for antibiotic synergy with benzothiazoles by Habjan, Eva, Lepioshkin, Alexander, Charitou, Vicky, Egorova, Anna, Kazakova, Elena, Ho, Vien QT, Bitter, Wilbert, Makarov, Vadim, Speer, Alexander

    Published in Life science alliance (01-07-2024)
    “…Developing effective tuberculosis drugs is hindered by mycobacteria's intrinsic antibiotic resistance because of their impermeable cell envelope. Using…”
    Get full text
    Journal Article
  7. 7

    Dysregulation of IMycobacterium marinum/I ESX-5 Secretion by Novel 1,2,4-oxadiazoles by Ho, Vien Q. T, Rong, Mark K, Habjan, Eva, Bommer, Samantha D, Pham, Thang V, Piersma, Sander R, Bitter, Wilbert, Ruijter, Eelco, Speer, Alexander

    Published in Biomolecules (Basel, Switzerland) (01-01-2023)
    “…The ESX-5 secretion system is essential for the viability and virulence of slow-growing pathogenic mycobacterial species. In this study, we identified a…”
    Get full text
    Journal Article